PharmGKB: The Pharmacogenomics Knowledge Base

Drug/Small Molecule:
risperidone

2D structure

Overview

Generic Names: Risperidona [Spanish]; Risperidonum [Latin]; risperdone; risperidone
Trade Names: Risperdal; Risperdal Consta; Risperdal M-Tab; Risperidal M-Tab; Risperin; Rispolept; Rispolin; Sequinan
PharmGKB Accession Id: PA451257

Description

A selective blocker of dopamine D2 receptors and serotonin 5-HT2 receptors that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of schizophrenia. PubChem (source: Drug Bank)

Indication

For the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. (source: Drug Bank)

ATC Therapeutic Category

  • N05AX:Other antipsychotics

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Blockade of dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia such as hallucinations, delusions, and erratic behavior and speech. Blockade of serotonergic 5-HT<sub>2</sub> receptors in the mesocortical tract, causes an excess of dopamine and an increase in dopamine transmission, resulting in an increase in dopamine transmission and an elimination of core negative symptoms. Dopamine receptors in the nigrostriatal pathway are not affected by risperidone and extrapyramidal effects are avoided. Like other 5-HT<sub>2</sub> antagonists, risperidone also binds at alpha(1)-adrenergic receptors and, to a lesser extent, at histamine H1 and alpha(2)-adrenergic receptors. (source: Drug Bank)

Pharmacology

Risperidone is an atypical antipsychotic medication. It is most often used to treat delusional psychosis (including schizophrenia), but risperidone is also used to treat some forms of bipolar disorder and psychotic depression. It also has shown some success in treating symptoms of Asperger's Syndrome and autism. Risperidone is now the most commonly prescribed antipsychotic medication in the United States. (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. (source: Drug Bank)

Protein Binding

90% (source: Drug Bank)

Absorption

Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution. (source: Drug Bank)

Toxicity

Symptoms of overdose include drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. LD<sub>50</sub>=82.1mg/kg (orally in mice). (source: Drug Bank)

Isomeric SMILES Code:

Cc1c(c(=O)n2c(n1)CCCC2)CCN3CCC(CC3)c4c5ccc(cc5on4)F (source: Drug Bank)

Curated Annotations (Curated Annotation)

  1. rs10917670 at chr1:161299466 in RGS4
    Results from a study in patients with acutely exacerbated schizophrenia suggest that this variant in the RGS4 gene influences clinical manifestations of schizophrenia as well as the treatment response to risperidone.
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:18204343
  2. rs951439 at chr1:161300315 in RGS4
    This variant is associated with differential antipsychotic treatment response in individuals of african descent. Patients with african descent and rs951439 genotype CC responded better to perphenazine treatment compared with ziprasidone or quetiapine treatments. Patient with European descent and rs951439 TT genotype responded better to risperidone than those with CC genotype. However, no association was find between this variant and incidence or age at onset in schizophrenia as well as treatment responses in Finnish patients.
    Related Drugs:
    perphenazine, quetiapine, risperidone, ziprasidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:16604300
    PMID:17588543
    PMID:18204343
  3. rs2661319 at chr1:161306401 in RGS4
    This variant is associated with differential antipsychotic treatment response in individuals of african descent and chinese descent.
    Related Drugs:
    perphenazine, quetiapine, risperidone, ziprasidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:17588543
    PMID:18204343
  4. rs2661319 at chr1:161306401 in RGS4
    Results from a study in patients with acutely exacerbated schizophrenia suggest that this variant in the RGS4 gene influences clinical manifestations of schizophrenia as well as the treatment response to risperidone.
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:18204343
  5. rs2842030 at chr1:161307119 in RGS4
    This variant is associated with differential antipsychotic treatment response in individuals of african descent. Patient with rs2842030 TT genotype responded better to perphenazine treatment than by quatiapine, risperidone or ziprasidone. Patient with European descent and rs2842030 GG genotype responded better to risperidone than those with TT genotype.No association was found between this variant and increased susceptibility to the etiology of schizophrenia in Han Chinese.
    Related Drugs:
    perphenazine, quetiapine, risperidone, ziprasidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:16904822
    PMID:17588543
  6. rs4606 at chr1:191047795 in RGS2
    This variant is located in the 3'-regulatory region of RGS2, and is known to influence RGS2 mRNA levels and protein expression. It has been shown to be associated antipsychotic-induced parkinsonism (AIP) with possible protective effect of the minor G allele of rs4606.
    Related Drugs:
    clozapine, olanzapine, risperidone
    Related Diseases:
    Parkinson Disease, Psychotic Disorders
    Evidence:
    PMID:18347610
  7. rs167771 at chr3:115358965 in DRD3
    Risk or phenotype-associated allele: G. Phenotype: The G variant of rs167771 was associated with increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone. Study size: 132. Study population/ethnicity: Patients with Schizophrenia or Bipolar disorder receiving antipsychotics; Caucasians; Spain; Catalonia. Significance metric(s): OR = 3.3; p = 0.00013. Type of association: PD.
    Variant Name:
    rs167771:G>A
    Related Drugs:
    risperidone
    Related Diseases:
    Bipolar Disorder, Dyskinesia, Drug-Induced, Dystonia, Hypokinesia, Muscle Rigidity, Schizophrenia, Tremor
    Evidence:
    PMID:19506579
  8. rs6280 at chr3:115373505 in DRD3
    Risk or phenotype-associated allele: C Phenotype: Carriers of the C variant (Gly) of DRD3:Ser9Gly had greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone, than TT homozygotes. Study size: 45 Study population/ethnicity: Children with Autism receiving risperidone Significance metric(s): p = 0.012 Type of association: PD
    Variant Name:
    DRD3 Ser9Gly, DRD3 rs6280 (c.25T>C, p.S9G), DRD3:Ser9Gly
    Related Drugs:
    risperidone
    Related Diseases:
    Autistic Disorder
    Evidence:
    PMID:19997080
  9. rs179997 at chr6:16426612 in ATXN1
    Phenotype: In a study population treated for 8 weeks with risperidone the patients with the A allele of the A-241G SNP showed greater improvement than those with the G allele on the overall Brief Psychiatric Rating Scale (chi2=7.19, p=0.00, p=0.031 after correction by the program SNPSpD). Study size: 125. Study population: Chinese.
    Variant Name:
    DRD2: A-241G
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:17105675
  10. rs724226 at chr7:86163310 in GRM3
    In a study of 78 African American and 65 white patients diagnosed with schizophrenia or schizoaffective disorder, this SNP in the GRM3 gene was found to have significant associations with response to risperidone over 2-12 weeks in both African-American and white patients.
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:19451915
  11. rs1128503 at chr7:87017537 in ABCB1
    Risk or phenotype-associated allele: T Phenotype: Carriers of the T variant of ABCB1:1236C>T had lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone, than CC homozygotes. Study size: 45 Study population/ethnicity: Children with Autism receiving risperidone Significance metric(s): p = 0.002 Type of association: PD
    Variant Name:
    ABCB1 1236C>T, ABCB1:1236C>T
    Related Drugs:
    risperidone
    Related Diseases:
    Autistic Disorder
    Evidence:
    PMID:19997080
  12. rs7799039 at chr7:127666019 in LEP
    Risk or phenotype-associated allele(s): G/G. Phenotype:the GG-genotype carriers were 2.5 times less likely to be overweight/obese (i.e. having a BMI above the 85th percentile). Study population/ethnicity: Children and adolescents, aged 7-17 years, treated with risperidone for 6 months or more.
    Variant Name:
    LEP: -2548G/A
    Related Drugs:
    risperidone
    Evidence:
    PMID:19873684
  13. rs1457266 at chr8:24825757 in NEFM
    A study in 121 acutely psychotic patients with DSM-IV schizophrenia receiving treatment with typical antipsychotic medication alone or plus risperidone showed that this variant in the NEF3 gene was associated with early response to the medication.
    Related Drugs:
    antipsychotics, risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:16734940
  14. rs1379357 at chr8:24837484
    A study in 121 acutely psychotic patients with DSM-IV schizophrenia receiving treatment with typical antipsychotic medication alone or plus risperidone showed that this variant in the NEF3 gene was associated with early response to the medication.
    Related Drugs:
    antipsychotics, risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:16734940
  15. rs2228622 at chr9:4554432 in SLC1A1
    Risk or phenotype-associated variant: A. Phenotype: The A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with atypical antipsychotic-induced obsessive compulsive symptoms. Study size: 94. Study population/ethnicity: Patients with schizophrenia receiving atypical antipsychotics; Asian; Korea. Significance metric(s): p = 0.04. Type of association: CO.
    Variant Name:
    SLC1A1:rs2228622G>A, SNP2, Exon 4(syn)
    Related Drugs:
    clozapine, olanzapine, risperidone
    Related Diseases:
    Obsessive-Compulsive Disorder, Schizophrenia
    Evidence:
    PMID:19884611
  16. rs3780413 at chr9:4557353 in SLC1A1
    Risk or phenotype-associated variant: C. Phenotype: The A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with atypical antipsychotic-induced obsessive compulsive symptoms. Study size: 94. Study population/ethnicity: Patients with schizophrenia receiving atypical antipsychotics; Asian; Korea. Significance metric(s): p = 0.04. Type of association: CO.
    Variant Name:
    SLC1A1:rss3780413C>G, SNP3, Intron 5
    Related Drugs:
    clozapine, olanzapine, risperidone
    Related Diseases:
    Obsessive-Compulsive Disorder, Schizophrenia
    Evidence:
    PMID:19884611
  17. rs3780412 at chr9:4562480 in SLC1A1
    Risk or phenotype-associated variant: G. Phenotype: The A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with atypical antipsychotic-induced obsessive compulsive symptoms. Study size: 94. Study population/ethnicity: Patients with schizophrenia receiving atypical antipsychotics; Asian; Korea. Significance metric(s): p = 0.04. Type of association: CO.
    Variant Name:
    SLC1A1:rs3780412A>G, SNP4, Intron 7
    Related Drugs:
    clozapine, olanzapine, risperidone
    Related Diseases:
    Obsessive-Compulsive Disorder, Schizophrenia
    Evidence:
    PMID:19884611
  18. rs1800497 at chr11:112776038 in ANKK1
    This SNP is significant predictor of treatment response to risperidone in first-episode schizophrenia.
    Variant Name:
    DRD2: TaqIA
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:18855532
  19. rs1800497 at chr11:112776038 in ANKK1
    Risk or phenotype-associated allele: T. Phenotype: Carriers of one or two copies of the T allele of this variant (also known as Taq1A A1) were at higher risk of developing hyperprolactinemia than those with two copies of the C allele (also known as Taq1A A2). This variant is a SNP located about 9.5 kb downstream of the DRD2 coding region, and results in a Glu (C allele) to Lys (T allele) amino acid substitution in the ANKK1 protein. Study size: 90. Study population/ethnicity: 7-17-year-old patients chronically treated with risperidone; non-Hispanic Caucasians. Significance metric(s): OR = 3.1; p < 0.05. Type of association: CO.
    Variant Name:
    DRD2:Taq1A A1
    Related Drugs:
    risperidone
    Related Diseases:
    Hyperprolactinemia
    Evidence:
    PMID:19339912
  20. rs1800497 at chr11:112776038 in ANKK1
    Phenotype: A meta-analysis, including eight individual studies, was not able to detect an association between clinical response to antipsychotics and the Taq1A variant. Study size: meta-analysis included 8 individual studies, 748 patients total.
    Variant Name:
    TaqIA (C/T)
    Related Drugs:
    aripiprazole, Bromperidol, chlorpromazine, clozapine, haloperidol, nemonapride, risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:20194480
  21. rs1800497 at chr11:112776038 in ANKK1
    Risk or phenotype-associated allele: T. Phenotype: In the combined medication group patients with the A1 (T) allele had 40% higher prolactin levels than patients without this allele. Study size: 144 schizophrenic patients. Study population: White patients.
    Variant Name:
    Taq1A (32806C>T)
    Related Drugs:
    antipsychotics, clozapine, olanzapine, risperidone
    Related Diseases:
    Hyperprolactinemia
    Evidence:
    PMID:15286066
  22. rs4436578 at chr11:112811975 in DRD2
    Risk or phenotype-associated allele: C Phenotype: Patients homozygous for the rs4436578-C allele were at increased risk of body weight gain as compared with the heterozygotes and those of the rs4436578-TT genotype after atypical antipsychotics treatment Study size: 479 chronic inpatients with schizophrenia Study population/ethnicity: Chinese Significance metric(s): OR = 3.36 (95% confidence interval=1.62 approximately 7.00) Type of association: GN
    Related Drugs:
    antipsychotics, clozapine, risperidone
    Evidence:
    PMID:20375926
  23. rs1799732 at chr11:112851462 in DRD2
    Risk or phenotype-associated genotype: Ins-A2/Ins-A2 diplotype. Phenotype: DRD2 Ins-A2/Del-A1 diplotype (n=10) compared with Ins-A2/Ins-A2 (n=25) diplotype may predict superior risperidone response in schizophrenic patients. Positive and Negative Syndrome Scale total scores of patients with Ins-A2/Del-A1 diplotype showed 40% greater improvement (P=0.03). Patients with other diplotypes did not differ significantly in any subscale scores or the total score. -141C Ins/Del (rs1799732); Taq1A (rs1800497; C32806T). Study size: 73 patients with schizophrenia. Study population: Japanese.
    Variant Name:
    DRD2: -141C Ins/Del
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:14610521
  24. rs1799732 at chr11:112851462 in DRD2
    Risk or phenotype-associated allele: Del. Phenotype: Carriers of the -141C Del allele showed significantly longer time to respond to the antipsychotics relative to the Ins/Ins homozygous patients (p<0.03). Study size: 61 patients experiencing their first episode of schizophrenia. Study population: 41% African American; 28% Caucasian (European); 18% Hispanic; 5% Asian; 8% other.
    Variant Name:
    DRD2: -141C Ins/Del
    Related Drugs:
    olanzapine, risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:16513877
  25. rs1799732 at chr11:112851462 in DRD2
    Phenotype: No association was found between the -141C Ins/Del polymorphism and response to risperidone. Study size: 125. Study population: Chinese.
    Variant Name:
    DRD2: -141C Ins/Del
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:17105675
  26. rs1799732 at chr11:112851462 in DRD2
    Phenotype: Results of this meta-analysis showed that the group of Del allele carrier was significantly associated with poorer antipsychotic drug response relative to the Ins/Ins genotype. Study size: meta-analysis included six individual studies, 687 patients total.
    Variant Name:
    DRD2: -141C Ins/Del
    Related Drugs:
    aripiprazole, chlorpromazine, clozapine, olanzapine, risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:20194480
  27. rs1799978 at chr11:112851561 in DRD2
    This SNP is significant predictor of treatment response to risperidone in first-episode schizophrenia.
    Variant Name:
    DRD2: -241A>G
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:18855532
  28. rs1799978 at chr11:112851561 in DRD2
    Risk or phenotype-associated allele: A. Phenotype: Having the AA genotype of this variant was associated with a protective effect from increased prolactin concentration. Study size: 90. Study population/ethnicity: 7-17-year-old patients chronically treated with risperidone; non-Hispanic Caucasians. Significance metric(s): p = 0.002. Type of association: CO.
    Variant Name:
    DRD2:A-241G
    Related Drugs:
    risperidone
    Related Diseases:
    Hyperprolactinemia
    Evidence:
    PMID:19339912
  29. rs6313 at chr13:46367941 in HTR2A
    Risk or phenotype-associated allele (s): T/T. Phenotype: Patients, with a diagnosis of probable Alzheimer's disease, carrying the TT genotype were the most delusional during the follow-up period of a study evaluating the association of HTR2A 102T/C polymorphism with psychotic symptom severity. Patients with delusion symptoms carrying the CT and TT genotypes were resistant to the treatment with antipsychotic drugs. Study size: 80. Study population/ethnicity: Caucasian
    Variant Name:
    HTR2A:T102C; HTR2A:102C>T
    Related Drugs:
    olanzapine, risperidone
    Related Diseases:
    Alzheimer Disease
    Evidence:
    PMID:19494443
  30. rs6311 at chr13:46369479 in HTR2A
    Risk or phenotype-associated allele: A Phenotype: Carriers of the A variant of HTR2A:(-1438)G>A had lower Autism Treatment Evaluation Checklist (ATEC) scores than GG homozygotes, indicating improved symptoms and response to risperidone. Study size: 45 Study population/ethnicity: Children with Autism receiving risperidone Significance metric(s): p = 0.019 Type of association: PD
    Variant Name:
    HTR2A c.-1438G>A, HTR2A:(-1438)G>A
    Related Drugs:
    risperidone
    Related Diseases:
    Autistic Disorder
    Evidence:
    PMID:19997080
  31. rs2494732 at chr14:104310237 in AKT1
    This SNP is significant predictor of treatment response to risperidone in first-episode schizophrenia.
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:18855532
  32. rs3803300 at chr14:104340824 in AKT1
    This SNP is significant predictor of treatment response to risperidone in first-episode schizophrenia.
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:18855532
  33. rs165599 at chr22:18336781 in ARVCF, COMT
    In a study of 78 African American and 65 white patients diagnosed with schizophrenia or schizoaffective disorder, this SNP in the COMT gene was found to have significant associations with response to risperidone over 2-12 weeks in both African-American and white patients.
    Related Drugs:
    risperidone
    Related Diseases:
    Schizophrenia
    Evidence:
    PMID:19451915
  34. rs3813928 at chrX:113724538 in HTR2C
    Risk or phenotype-associated allele: A Phenotype: Carriers of the A variant of HTR2C:(-995)G>A had higher Autism Treatment Evaluation Checklist (ATEC) scores, indicating worse symptoms and a poorer response to risperidone, than G homozygotes. Study size: 45 Study population/ethnicity: Children with Autism receiving risperidone Significance metric(s): p = 0.035 Type of association: PD
    Variant Name:
    HTR2C c.-995G>A, HTR2C:(-995)G>A
    Related Drugs:
    risperidone
    Related Diseases:
    Autistic Disorder
    Evidence:
    PMID:19997080
  35. rs1414334 at chrX:114044400 in HTR2C
    In a pooled analysis of two studies the variant C allele was specifically associated with the metabolic syndrome in patients using clozapine or risperidone.
    Related Drugs:
    clozapine, risperidone
    Related Diseases:
    metabolic syndrome
    Evidence:
    PMID:19142101
Variant names are different names that have been used in the literature and other resources to refer to the same variant.

The following genes are in curated knowledge about this drug.

  Gene Relationship Evidence
Phenotype data available Genotype Data Available Literature annotations available Has annotations
ABCB1
  • CO
  • PD
  • PK
  •   
  • GN
Publications, Variants
Phenotype data available Genotype Data Available Literature annotations available Has annotations
ACE
  •   
  • PD
  •   
  •   
  • GN
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
AKT1
  • CO
  •   
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
ANKK1
  •   
  •   
  •   
  •   
  •   
Variants
No phenotype data Genotype Data Available No literature annotations Not annotated
ARVCF
  •   
  •   
  •   
  •   
  •   
Variants
No phenotype data No genotype data No literature annotations Not annotated
ATXN1
  •   
  •   
  •   
  •   
  •   
Variants
No phenotype data No genotype data Literature annotations available Not annotated
BDNF
  •   
  •   
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
COMT
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP2D6
  • CO
  • PD
  • PK
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
CYP3A
  •   
  •   
  • PK
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP3A4
  •   
  •   
  • PK
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
CYP3A5
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Has annotations
DRD2
  • CO
  • PD
  • PK
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
DRD3
  •   
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
DRD4
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
GRM3
  •   
  •   
  •   
  •   
  • GN
Publications, Variants
No phenotype data Genotype Data Available Literature annotations available Not annotated
HTR2A
  •   
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data Genotype Data Available Literature annotations available Not annotated
HTR2C
  • CO
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
HTR3A
  • CO
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
HTR6
  •   
  •   
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Has annotations
KCNH2
  •   
  • PD
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
LEP
  •   
  •   
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
LEPR
  •   
  •   
  •   
  •   
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
MAOA
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
MAOB
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
NEFM
  •   
  •   
  •   
  •   
  •   
Variants
No phenotype data No genotype data Literature annotations available Not annotated
NPY5R
  •   
  •   
  •   
  •   
  • GN
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
PON1
  •   
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
PRKCB
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
RGS2
  •   
  •   
  •   
  •   
  •   
Variants
No phenotype data No genotype data Literature annotations available Not annotated
RGS4
  •   
  •   
  •   
  •   
  •   
Variants
No phenotype data No genotype data Literature annotations available Not annotated
SLC1A1
  • CO
  •   
  •   
  •   
  •   
Publications
No phenotype data Genotype Data Available Literature annotations available Not annotated
SLC6A3
  •   
  • PD
  •   
  •   
  • GN
Publications

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
HTR2A Uncurated Annotation (source: Drug Bank)
ADRA1A Uncurated Annotation (source: Drug Bank)
ADRA1B Uncurated Annotation (source: Drug Bank)
ADRB1 Uncurated Annotation (source: Drug Bank)
DRD2 Uncurated Annotation (source: Drug Bank)
HRH1 Uncurated Annotation (source: Drug Bank)

The following drugs are in curated knowledge about this drug.

  Drug Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
paroxetine
  •   
  •   
  •   
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
rifampin
  •   
  •   
  • PK
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
tamoxifen
  •   
  •   
  •   
  •   
  •   
Publications

A list of non-curated publications that mention this drug along with other drugs is available.

Curated Information

The following diseases are in curated knowledge about this drug.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
Autism Spectrum Disorder
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Bipolar Disorder
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Body Weight Changes
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Dyskinesia, Drug-Induced
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Dystonia
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Hyperprolactinemia
  •   
  • PD
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Hypokinesia
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Metabolic Diseases
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
metabolic syndrome
  •   
  •   
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Metabolic Syndrome X
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Muscle Rigidity
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Obsessive-Compulsive Disorder
  • CO
  •   
  •   
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Parkinson Disease
  •   
  • PD
  •   
  •   
  •   
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Psychotic Disorders
  • CO
  •   
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Schizophrenia
  • CO
  • PD
  • PK
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Tremor
  •   
  • PD
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Weight gain
  •   
  •   
  •   
  • FA
  • GN
Publications

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00734
KEGG Drug ID:
D00426
PubChem Compound ID:
5073
PubChem Substance ID:
7847492
IUPHAR Ligand ID:
96

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.